The effect of neo-adjuvant chemotherapy on the improvement of oral cancer patients and the predictive value of miR-182 on its efficacy.

PURPOSE This study aimed to observe the effect of neo-adjuvant chemotherapy on the improvement of oral cancer patients and investigate the predictive value of miR-182 on its efficacy. METHODS A total of 143 patients with advanced oral cancer admitted to Yidu Central Hospital of Weifang from September 2015 to July 2017 formed the study group. Among them, there were 62 cases in the control group (surgery+postoperative radiotherapy) and 81 cases in the study group (preoperative neo-adjuvant chemotherapy+surgery+postoperative radiotherapy). The treatment effect and adverse reactions of patients were compared between the two groups. RT-PCR was used to detect the expression levels of serum miR-182 of patients before and after treatment. The 1-year survival of patients in the two groups was recorded and compared by follow-up. RESULTS The total effective rate of patients in the study group was significantly higher than that of patients in the control group (p<0.05). The incidence of adverse reactions of patients in the study group was significantly higher than in the control group (p<0.05). There was no significant difference in the prognostic 1-year survival rate between the two groups. After treatment, the expression of miR-182 was lower than before treatment and in the study group it was significantly lower than the control group (p<0.05). ROC curve analysis showed that the area under the curve of miR-182 in the predictive value of oral cancer was 0.756. When the cut-off value was less than 1.823, the optimal specificity was 70.18% and the sensitivity was 75.86%. CONCLUSION Neo-adjuvant chemotherapy can significantly improve the therapeutic effect, but the incidence of adverse reactions increases. miR-182 may be involved in the occurrence and deterioration of oral cancer and is a good indicator for predicting the treatment efficacy of patients with oral cancer.